Sumitomo Dainippon Ownership

DNPUFDelisted Stock  USD 4.37  0.00  0.00%   
Sumitomo Dainippon Pharma shows a total of 397.29 Million outstanding shares. Sumitomo Dainippon Pharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Sumitomo Pink Sheet Ownership Analysis

About 59.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.64. Some equities with similar Price to Book (P/B) outperform the market in the long run. Sumitomo Dainippon Pharma last dividend was issued on the 30th of March 2023. The entity had 21:20 split on the 26th of March 1992. Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Dai Nippon operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 6987 people.The quote for Sumitomo Dainippon Pharma is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Sumitomo Dainippon Pharma call the company at 81 6 6203 5321 or check out https://www.sumitomo-pharma.com.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in Sumitomo Pink Sheet

If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum